SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-000240
Filing Date
2024-01-02
Accepted
2024-01-02 08:00:55
Documents
12
Period of Report
2023-12-29
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K d682377d8k.htm   iXBRL 8-K 30147
  Complete submission text file 0001193125-24-000240.txt   154173

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tcrt-20231229.xsd EX-101.SCH 2841
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tcrt-20231229_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tcrt-20231229_pre.xml EX-101.PRE 11255
6 EXTRACTED XBRL INSTANCE DOCUMENT d682377d8k_htm.xml XML 3352
Mailing Address 2617 BISSONNET ST SUITE 225 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 225 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

IRS No.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 24500289
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)